Sports doping: Emerging designer and therapeutic B2-agonists

A.G. Fragkaki, C. Georgakopoulos, S.S. Sterk, M.W.F. Nielen

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)

Abstract

Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
Original languageEnglish
Pages (from-to)242-258
Number of pages17
JournalClinica Chimica Acta
Volume425
DOIs
Publication statusPublished - 2013

Fingerprint

Sports
Adrenergic beta-2 Receptor Agonists
Doping (additives)
Essential Drugs
Anabolic Agents
Molecules
Bronchodilator Agents
Therapeutic Uses
European Union
Growth
Adrenal Cortex Hormones
Asthma
Therapeutics
Derivatives
Controllers
Pharmaceutical Preparations
Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate
indole
N-phenylurea

Keywords

  • acting beta(2)-adrenoreceptor agonists
  • chromatography-mass spectrometry
  • molecularly imprinted polymers
  • obstructive pulmonary-disease
  • beta-adrenergic agonists
  • performance liquid-chromatography
  • 2-dimensional gas-chromatography
  • developed bronchodilati

Cite this

Fragkaki, A.G. ; Georgakopoulos, C. ; Sterk, S.S. ; Nielen, M.W.F. / Sports doping: Emerging designer and therapeutic B2-agonists. In: Clinica Chimica Acta. 2013 ; Vol. 425. pp. 242-258.
@article{4643a335e2b549e98be71f3eeacb6ab0,
title = "Sports doping: Emerging designer and therapeutic B2-agonists",
abstract = "Beta2-adrenergic agonists, or {\ss}2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of {\ss}2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel {\ss}2-agonists molecules either by modifying the molecule of known {\ss}2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging {\ss}2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.",
keywords = "acting beta(2)-adrenoreceptor agonists, chromatography-mass spectrometry, molecularly imprinted polymers, obstructive pulmonary-disease, beta-adrenergic agonists, performance liquid-chromatography, 2-dimensional gas-chromatography, developed bronchodilati",
author = "A.G. Fragkaki and C. Georgakopoulos and S.S. Sterk and M.W.F. Nielen",
year = "2013",
doi = "10.1016/j.cca.2013.07.031",
language = "English",
volume = "425",
pages = "242--258",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

Sports doping: Emerging designer and therapeutic B2-agonists. / Fragkaki, A.G.; Georgakopoulos, C.; Sterk, S.S.; Nielen, M.W.F.

In: Clinica Chimica Acta, Vol. 425, 2013, p. 242-258.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Sports doping: Emerging designer and therapeutic B2-agonists

AU - Fragkaki, A.G.

AU - Georgakopoulos, C.

AU - Sterk, S.S.

AU - Nielen, M.W.F.

PY - 2013

Y1 - 2013

N2 - Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.

AB - Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.

KW - acting beta(2)-adrenoreceptor agonists

KW - chromatography-mass spectrometry

KW - molecularly imprinted polymers

KW - obstructive pulmonary-disease

KW - beta-adrenergic agonists

KW - performance liquid-chromatography

KW - 2-dimensional gas-chromatography

KW - developed bronchodilati

U2 - 10.1016/j.cca.2013.07.031

DO - 10.1016/j.cca.2013.07.031

M3 - Article

VL - 425

SP - 242

EP - 258

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -